Program
ibutamoren
Also written as “LUM-201” and “MK0677”.
Its studies are mostly in Dwarfism, Pituitary · Obesity · Hip Fractures · Alzheimer Disease, led by 2 companies.
Drug pageIbutamoren: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lumos Pharmaits history only | 75 open or running | phase 3since Apr 21, 2025 | Oct 26, 2020 | Dec 2027phase 3 · NCT06948214 |
| Merck | 20 open or running | phase 2since Dec 15, 2003 | Dec 15, 2003 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2003First study: phase 2 study in Alzheimer DiseaseFirst studyNCT00074529 · 512 enrolled
- Aug 5, 2005Phase 2 study in Hip FracturesNCT00128115 · 83 enrolled · Germany, Norway, Spain and more
TargetBeta
“Ghrelin receptor agonist”ChEMBL 37, by rule
Studies
All 2 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00128115Hip Fractures · Germany, Norway, Spain and more | 2 | Terminated | Aug 2007 | 83 |
| NCT00074529Alzheimer Disease | 2 | Completed | Jan 2006 | 512 |
How it is read
Names in the registry
- “LUM-201”, 7 entries
- “MK0677”, 2 entries
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 6 studies
- Obesity, 1 study
- Hip Fractures, 1 study
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.